🔴 LifeMD is trading 10.73% down today after Q2 revenue miss and reduced 2026 guidance

LifeMD is trading 10.73% down at $3.33 after its August 5, 2026 earnings release showed Q2 revenue below analyst expectations and cut 2026 guidance.

• Q2 revenue: $47.3 million; adjusted EBITDA loss: approximately $3.5 million.
• Full-year revenue guidance fell to $205.5–$212.5 million from $220–$230 million; adjusted EBITDA guidance to negative $6 million–breakeven.
• Shares fell 5.64% to $3.68 on August 5; management cited branded GLP-1 transition, pricing changes and XYOSTED launch costs as healthcare was broadly stronger.